Opinion

Video

Patient Case Studies of GvHD

Provide detailed case studies highlighting the development, clinical presentation, multidisciplinary management, and outcomes of patients with acute and chronic GvHD following allo-HSCT.

This is a video synopsis/summary of a Peer Exchange featuring Miguel-Angel Perales, MD; Nelli Bejanyan, MD; Amandeep Salhotra, MD; and Arpita Gandhi, MD, MS.

The panel discusses the challenge of relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT), which remains the leading cause of mortality in this setting. Regardless of the donor type, about 50% of patients who die after 100 days of allogeneic transplantation succumb to relapse. Prevention of relapse is crucial, as treatment options for post-transplant relapse are limited.

A Center for International Blood and Marrow Transplant Research study reported in 2015 showed that among 1800 patients who relapsed after allogeneic transplantation, only 30% achieved subsequent complete remission with chemotherapy, and these remissions were not durable. Patients who appeared to benefit in terms of survival were those who received a second allogeneic transplantation or donor lymphocyte infusion (DLI). However, only 17% of patients were candidates for a subsequent allogeneic transplantation.

The timing of relapse is a critical predictor of subsequent survival. Patients who relapse within the first 6 months have a 1-year survival of only 4%, while those who relapse after 2 or more years, particularly at 3 to 4 years, can be salvaged with subsequent cellular-based therapy, such as DLI or DLI followed by a second allogeneic transplantation, with 30% to 40% achieving long-term survival.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.

Related Videos
David C. Fisher, MD
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Yair Lotan, MD, UT Southwestern Medical Center